Why Packaging Is Now a Frontline Issue In Pharma Supply Chains

Pharmaceutical supply chains are being pushed into a level of coordination and control they were not originally designed to handle.

Therapies are becoming more sensitive, more valuable and less tolerant of variation. At the same time, the logistics environments they move through are becoming less stable. Weather disruptions, congestion at major hubs, cargo theft and shifting global trade routes are now recurring conditions where they were previously isolated events.

On the surface, many of these challenges appear to be logistics problems. In practice, they are exposing something deeper. Protecting high-value medications, biologics and personalized medicines goes beyond packaging alone. The cold chain is no longer a controlled environment; it is a dynamic system operating under constant disruption.

That is forcing a reset in how protection is defined.

Packaging is No Longer a Passive Layer – It Requires Oversight

In the 100 years since the dawn of electric refrigeration, humans' ability to keep things cool has advanced significantly. There are few places where that progress is more evident than cold chain packaging. Insulation materials, phase change systems and more are now standard engineering for maintaining temperature across longer durations and more extreme conditions.

The problem is that these systems were built on assumptions.

Their success assumes that a shipment will move within a defined transit window, that exposure conditions will stay within tested ranges, or that handoffs between partners will happen as planned. These assumptions are breaking more frequently as variability becomes the new supply chain norm.

Here’s what those breakdowns can look like in practice: a biologic shipment delayed at an airport transfer hub can sit on a tarmac for hours in high heat. A lane that historically cleared customs in six hours can take 24. A shipment flagged for inspection may experience temperature fluctuations that packaging was never designed to absorb.

In each case, the shipment's packaging still does exactly what it was designed to do. But ultimately, packaging can only perform within its limits, and those limits are being pushed to the edge of what they can withstand often.

This is why packaging is now a frontline issue. Not because it has become less important, but because it has become more exposed.

How Are Advanced Therapies Exposing Blind Spots in Cold Chain Control?

The shift in cold chain risk starts with the shipments themselves.

Biologics, cell and gene therapies, and personalized medicine have redefined acceptable risk in pharmaceutical logistics. Many require strict temperature control at -20°C, -80°C, or below. These therapies are also time-critical and high value. A single shipment can represent hundreds of thousands of dollars in development and production. For patient-specific therapies, the consequence is not just financial; a compromised shipment can delay or eliminate a treatment window entirely.

At the same time, the way these therapies move is becoming more complex. Multi-leg international routes, decentralized manufacturing, and smaller, more frequent shipments increase the number of handoffs across partners and geographies. Each handoff introduces variability that compounds across the life of the shipment.

For logistics providers handling advanced therapies at scale, this risk profile leaves no margin for error. One operator managing tens of thousands of life sciences shipments annually ultimately moved to real-time monitoring across all shipments because, in their mind, there is simply no option for failure when transporting cell and gene therapies.

How Does Real-Time Visibility Move Decision-Making Into Transit?

The difference between product loss and recovery is timing. Traditional cold chain models detect issues after delivery—but modern cold chains require decisions during transit.

Packaging is designed to protect within expected conditions; it cannot adapt to compounded delays, exposure, or handling variability. Legacy monitoring approaches reinforce this limitation by taking a reactive approach to temperature logging, often reviewing in-transit temperature data after delivery. This assumes that what happens during shipping (and between actual checkpoints) is stable—and if it’s not, there’s no way to adapt.

Real-time visibility changes the timing of decisions. Continuous monitoring of temperature, location, and environmental conditions enables teams to see where risk is developing, not just that it occurred. For example, when a shipment is delayed at a transfer hub, real-time data can show both current temperature and the rate of change. Teams can estimate how much thermal protection remains and determines whether intervention is required. Without visibility, risk accumulates unnoticed. With visibility, teams can act while a shipment is still recoverable.

For organizations moving diagnostic samples and patient materials, this shift is operational, not theoretical. One company noted that before implementing real-time tracking, “we had no real way to understand what happened” when shipments were delayed. With full visibility, teams can now trace exactly where and how disruptions occur—and intervene accordingly.

Visibility also enables a second layer of value. When analyzed over time, shipment data reveal patterns. Excursions are rarely isolated events: they are often tied to specific lanes, hubs, or handling conditions. A typical shipment may cross multiple countries, regulatory environments, and partners—and over time, patterns emerge. Certain lanes show recurring temperature variability. Certain regions introduce consistent exposure risk.

These patterns are not visible at the shipment level. Addressing them often reduces risk more effectively than changing packaging alone.

Why Does Control Now Depend on Visibility, Response, and System Design?

The shift underway in the cold chain is not about improving packaging performance. It is about redefining control.

For years, protection was measured by whether packaging could hold temperature under expected conditions. That model no longer reflects how pharmaceutical supply chains operate. Control now depends on what actually happens during transit.

That starts with visibility. Teams need to understand not just where a shipment is, but how conditions are changing over time, where delays are occurring, and how quickly risk is building. Without that insight, every decision is delayed—and every response comes too late.

High-performing teams are moving from monitoring shipments to managing them. They define what triggers action, who owns the response, and how to coordinate across carriers and partners when conditions change mid-transit. This requires alignment between data and execution. Alerts must lead to decisions. Decisions must lead to intervention. Intervention must happen while a shipment is still recoverable.

When executed effectively, this model has a measurable impact. Internal modeling shows that a life sciences shipper moving roughly 500 shipments per month can reduce losses and inefficiencies by tens of thousands of dollars monthly—translating to upwards of $800,000 a year—simply by identifying and acting on in-transit risk earlier.

Over time, this approach changes how performance is measured. Excursions become signals. Patterns across lanes, hubs, and partners show where variability is being introduced—and where it can be reduced. In many cases, the root cause is not the packaging. It is the system the packaging operates within.

A New Baseline for Cold Chain Performance

The pharmaceutical cold chain is no longer defined by whether products arrive within specification. It is defined by how effectively organizations manage risk in transit.

Packaging remains essential, but it is no longer sufficient on its own. Control now depends on visibility, timing, and the ability to act before conditions cross a critical threshold.

The organizations that adapt to this model are not eliminating disruption. They are building systems that can absorb it, respond to it, and improve from it over time.

That is the new baseline for cold chain performance.

Alex Guillen is global subject matter expert, life sciences & pharma, at Tive.